Philly Biotech Is On It

From our region’s epicenter of discovery, Greater Philadelphia researchers and companies are part of the global race to get a handle on COVID-19, including Biomeme, The Wistar Institute, and the newly formed Penn Center for Research on Coronaviruses and Other Emerging Pathogens (PENNCoV).

Article from The Philadelphia Citizen

Biotech company with U.S. headquarters in Montco raises $130 million in series B

The biotech company Immunocore, with its U.S. headquarters in Montgomery County, announced a $130 million Series B financing round to continue the development of T-cell receptor therapies.

Article from the Philadelphia Business Journal

Penn gene therapy spinout exceeds projections with $216M IPO

Penn Medicine spinout Passage Bio raised $216 million through an initial public offering to support the continued development of clinical trials for gene therapies to treat rare central nervous system disorders – exceeding expectations and proving that cell and gene therapies can thrive in the Greater Philadelphia region.

Article from the Philadelphia Business Journal

Philadelphia gene therapy startup plans $125M IPO

Another life sciences IPO for Greater Philadelphia: Gene therapy startup Passage Bio plans to go public via a $125 million IPO, to continue developing six gene therapy candidates for central nervous system diseases, including dementia.

Article from the Philadelphia Business Journal

5 Predictions for Philadelphia’s Cell and Gene Therapy Sector in 2020

What’s next for the Greater Philadelphia region as a global hub for cell and gene therapy and connected health? Dan Hilferty of Independence Blue Cross shares his predictions for 2020.

Article from Philadelphia magazine

Philadelphia gene therapy company battling cystic fibrosis gets a new owner

Philadelphia-based gene therapy company Spirovant was acquired by Sumitomo Dainippon Pharma, of Japan in a $3 billion deal. They will remain here in the region and continue the development of two therapies to treat cystic fibrosis.

Article from the Philadelphia Business Journal

Three local life sciences companies raise nearly $200M in 2019 IPOs

University of Pennsylvania spinout Cabaletta Bio raised $74.8 million in October, selling 6.8 million shares of common stock at $11 per share.

Article from the Philadelphia Business Journal

Penn spinout developing cancer treatments raises $1M

Pinpoint Therapeutics, a University of Pennsylvania spinout focused on developing cancer treatments, has raised $1 million in debt financing.

Article from the Philadelphia Business Journal

Adaptimmune gets FDA designation to accelerate development of cancer therapy

Adaptimmune’s cell therapy to treat synovial sarcoma – a type of cancer – was designated as a regenerative medicine advanced therapy by the FDA. The designation qualifies the therapy for expedited development and review.

Article from the Philadelphia Business Journal

LLR invests $40M in Montgomery County clinical trial software company

Suvoda, a Conshohocken-based clinical trial software and services company, raised more than $40 million in an equity financing deal from private equity firm LLR Partners.

Article from the Philadelphia Business Journal